StockData

Alnylam Pharmaceuticals vs Arrowhead Pharmaceuticals

ALNY and ARWR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALNY and ARWR compare

Alnylam Pharmaceuticals is the larger company, worth 2.6 times as much as Arrowhead Pharmaceuticals ($22.1B against $8.5B).

Alnylam Pharmaceuticals scores higher on the StockData Score (7 against 5 for Arrowhead Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALNYARWR
Size and price
Market cap$22.1B$8.5B
Share price$165.00$59.90
Change, 1 year−65.7%48.7%
Change, 5 years−11.9%−25.8%
Beta (5Y)0.881.73
Employees2,500711
StockData Score
Total score7 (better)5
Valuation score00
Growth score12 (better)
Performance score12 (better)
Health score5 (better)1
Dividend score00
Valuation
P/S–12.6×
P/B6.1× (better)18.2×
FCF yield–−0.89%
Fair value–$32.22
Margin of safety–−85.9%
Growth
Revenue growth (TTM)–16.8%
Revenue growth, 5Y average49.8%56.6% (better)
Net income growth (TTM)2137%–
Profitability
Operating margin–−33.8%
Net margin–−47.8%
FCF margin–−11.2%
Return on equity127% (better)−64.8%
Financial health
Debt / equity0.00–
Interest coverage–−2.4×
Current ratio2.485.90 (better)
Altman Z-score2.75 (better)2.56
Piotroski F-score6 (better)5
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions99.8%84.6%
Held by insiders0.49%4.0%
Insider net buying, 12 months−$43.6M−$37.3M (better)
Short interest, % of float5.8%7.9%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.